Long-term safety and efficacy of nevirapine-based approaches in HIV type 1-infected patients

Anna Bonjoch, Roger Paredes, Pere Domingo, Manel Cervantes, Enric Pedrol, Esteve Ribera, Lluís Force, Josep M. Llibre, Josep Vilaró, David Dalmau, Josep Cucurull, Jaume Mascaró, Angels Masabeu, Núria Pérez-Álvarez, Jordi Puig, Denise Cinquegrana, Bonaventura Clotet

Research output: Contribution to journalArticle

Abstract

Using a multicenter, cross-sectional, observation study, the long-term safety, metabolic profile, and viral efficacy of nevirapine (NVP)-based approaches in HIV-1-infected patients treated for at least 2 years were assessed. For 4 months, all consecutive HIV-1-infected patients who had been receiving an NVP-containing regimen for at least 2 years were recruited. A total of 613 patients were included with a median follow-up period of 43 months (IQR: 31-51). At baseline, 24.5% (150 patients) were treatment naive, 41.5% (254 patients) switched for simplification purposes, and 34% (209 patients) were failing HAART. Increases by five times or more in AST/ALT values were observed in fewer than 2% of patients. Only 5.7% of all adverse events reported during the investigation were attributable to NVP. The percentage of patients with normal HDL cholesterol levels rose from 17.7% at baseline to 35.4% at the last visit. At the latest time point available for analysis, 76% of naive and 74% of those who had switched had HIV-1 RNA loads of <50 copies/ml, while 59% of salvage patients achieved this level of viral suppression. Factors associated with viral suppression at the latest visit were adequate adherence (OR: 2.58, 95% CI: 0.85-7.78, p < 0.001), first-line treatment (OR: 3.02, 95% CI: 1.52-6.00, p = 0.002), and baseline CD4 cells >400 cells/μl (OR: 2.34, 95% CI: 1.22-4.47, p = 0.010). Exposure to nevirapine for up to 4 years is safe. Liver toxicity is infrequent and generally mild. HDL cholesterol levels consistently increase over time and viral suppression is maintained.

Original languageEnglish (US)
Pages (from-to)321-329
Number of pages9
JournalAIDS Research and Human Retroviruses
Volume22
Issue number4
DOIs
StatePublished - Apr 1 2006
Externally publishedYes

Fingerprint

Nevirapine
HIV-1
Safety
HDL Cholesterol
Metabolome
Highly Active Antiretroviral Therapy
Cross-Sectional Studies
Observation
RNA
Liver

ASJC Scopus subject areas

  • Immunology
  • Virology
  • Infectious Diseases

Cite this

Bonjoch, A., Paredes, R., Domingo, P., Cervantes, M., Pedrol, E., Ribera, E., ... Clotet, B. (2006). Long-term safety and efficacy of nevirapine-based approaches in HIV type 1-infected patients. AIDS Research and Human Retroviruses, 22(4), 321-329. https://doi.org/10.1089/aid.2006.22.321

Long-term safety and efficacy of nevirapine-based approaches in HIV type 1-infected patients. / Bonjoch, Anna; Paredes, Roger; Domingo, Pere; Cervantes, Manel; Pedrol, Enric; Ribera, Esteve; Force, Lluís; Llibre, Josep M.; Vilaró, Josep; Dalmau, David; Cucurull, Josep; Mascaró, Jaume; Masabeu, Angels; Pérez-Álvarez, Núria; Puig, Jordi; Cinquegrana, Denise; Clotet, Bonaventura.

In: AIDS Research and Human Retroviruses, Vol. 22, No. 4, 01.04.2006, p. 321-329.

Research output: Contribution to journalArticle

Bonjoch, A, Paredes, R, Domingo, P, Cervantes, M, Pedrol, E, Ribera, E, Force, L, Llibre, JM, Vilaró, J, Dalmau, D, Cucurull, J, Mascaró, J, Masabeu, A, Pérez-Álvarez, N, Puig, J, Cinquegrana, D & Clotet, B 2006, 'Long-term safety and efficacy of nevirapine-based approaches in HIV type 1-infected patients', AIDS Research and Human Retroviruses, vol. 22, no. 4, pp. 321-329. https://doi.org/10.1089/aid.2006.22.321
Bonjoch, Anna ; Paredes, Roger ; Domingo, Pere ; Cervantes, Manel ; Pedrol, Enric ; Ribera, Esteve ; Force, Lluís ; Llibre, Josep M. ; Vilaró, Josep ; Dalmau, David ; Cucurull, Josep ; Mascaró, Jaume ; Masabeu, Angels ; Pérez-Álvarez, Núria ; Puig, Jordi ; Cinquegrana, Denise ; Clotet, Bonaventura. / Long-term safety and efficacy of nevirapine-based approaches in HIV type 1-infected patients. In: AIDS Research and Human Retroviruses. 2006 ; Vol. 22, No. 4. pp. 321-329.
@article{65ec6eb1e95a4f50be204f6898a81d2c,
title = "Long-term safety and efficacy of nevirapine-based approaches in HIV type 1-infected patients",
abstract = "Using a multicenter, cross-sectional, observation study, the long-term safety, metabolic profile, and viral efficacy of nevirapine (NVP)-based approaches in HIV-1-infected patients treated for at least 2 years were assessed. For 4 months, all consecutive HIV-1-infected patients who had been receiving an NVP-containing regimen for at least 2 years were recruited. A total of 613 patients were included with a median follow-up period of 43 months (IQR: 31-51). At baseline, 24.5{\%} (150 patients) were treatment naive, 41.5{\%} (254 patients) switched for simplification purposes, and 34{\%} (209 patients) were failing HAART. Increases by five times or more in AST/ALT values were observed in fewer than 2{\%} of patients. Only 5.7{\%} of all adverse events reported during the investigation were attributable to NVP. The percentage of patients with normal HDL cholesterol levels rose from 17.7{\%} at baseline to 35.4{\%} at the last visit. At the latest time point available for analysis, 76{\%} of naive and 74{\%} of those who had switched had HIV-1 RNA loads of <50 copies/ml, while 59{\%} of salvage patients achieved this level of viral suppression. Factors associated with viral suppression at the latest visit were adequate adherence (OR: 2.58, 95{\%} CI: 0.85-7.78, p < 0.001), first-line treatment (OR: 3.02, 95{\%} CI: 1.52-6.00, p = 0.002), and baseline CD4 cells >400 cells/μl (OR: 2.34, 95{\%} CI: 1.22-4.47, p = 0.010). Exposure to nevirapine for up to 4 years is safe. Liver toxicity is infrequent and generally mild. HDL cholesterol levels consistently increase over time and viral suppression is maintained.",
author = "Anna Bonjoch and Roger Paredes and Pere Domingo and Manel Cervantes and Enric Pedrol and Esteve Ribera and Llu{\'i}s Force and Llibre, {Josep M.} and Josep Vilar{\'o} and David Dalmau and Josep Cucurull and Jaume Mascar{\'o} and Angels Masabeu and N{\'u}ria P{\'e}rez-{\'A}lvarez and Jordi Puig and Denise Cinquegrana and Bonaventura Clotet",
year = "2006",
month = "4",
day = "1",
doi = "10.1089/aid.2006.22.321",
language = "English (US)",
volume = "22",
pages = "321--329",
journal = "AIDS Research and Human Retroviruses",
issn = "0889-2229",
publisher = "Mary Ann Liebert Inc.",
number = "4",

}

TY - JOUR

T1 - Long-term safety and efficacy of nevirapine-based approaches in HIV type 1-infected patients

AU - Bonjoch, Anna

AU - Paredes, Roger

AU - Domingo, Pere

AU - Cervantes, Manel

AU - Pedrol, Enric

AU - Ribera, Esteve

AU - Force, Lluís

AU - Llibre, Josep M.

AU - Vilaró, Josep

AU - Dalmau, David

AU - Cucurull, Josep

AU - Mascaró, Jaume

AU - Masabeu, Angels

AU - Pérez-Álvarez, Núria

AU - Puig, Jordi

AU - Cinquegrana, Denise

AU - Clotet, Bonaventura

PY - 2006/4/1

Y1 - 2006/4/1

N2 - Using a multicenter, cross-sectional, observation study, the long-term safety, metabolic profile, and viral efficacy of nevirapine (NVP)-based approaches in HIV-1-infected patients treated for at least 2 years were assessed. For 4 months, all consecutive HIV-1-infected patients who had been receiving an NVP-containing regimen for at least 2 years were recruited. A total of 613 patients were included with a median follow-up period of 43 months (IQR: 31-51). At baseline, 24.5% (150 patients) were treatment naive, 41.5% (254 patients) switched for simplification purposes, and 34% (209 patients) were failing HAART. Increases by five times or more in AST/ALT values were observed in fewer than 2% of patients. Only 5.7% of all adverse events reported during the investigation were attributable to NVP. The percentage of patients with normal HDL cholesterol levels rose from 17.7% at baseline to 35.4% at the last visit. At the latest time point available for analysis, 76% of naive and 74% of those who had switched had HIV-1 RNA loads of <50 copies/ml, while 59% of salvage patients achieved this level of viral suppression. Factors associated with viral suppression at the latest visit were adequate adherence (OR: 2.58, 95% CI: 0.85-7.78, p < 0.001), first-line treatment (OR: 3.02, 95% CI: 1.52-6.00, p = 0.002), and baseline CD4 cells >400 cells/μl (OR: 2.34, 95% CI: 1.22-4.47, p = 0.010). Exposure to nevirapine for up to 4 years is safe. Liver toxicity is infrequent and generally mild. HDL cholesterol levels consistently increase over time and viral suppression is maintained.

AB - Using a multicenter, cross-sectional, observation study, the long-term safety, metabolic profile, and viral efficacy of nevirapine (NVP)-based approaches in HIV-1-infected patients treated for at least 2 years were assessed. For 4 months, all consecutive HIV-1-infected patients who had been receiving an NVP-containing regimen for at least 2 years were recruited. A total of 613 patients were included with a median follow-up period of 43 months (IQR: 31-51). At baseline, 24.5% (150 patients) were treatment naive, 41.5% (254 patients) switched for simplification purposes, and 34% (209 patients) were failing HAART. Increases by five times or more in AST/ALT values were observed in fewer than 2% of patients. Only 5.7% of all adverse events reported during the investigation were attributable to NVP. The percentage of patients with normal HDL cholesterol levels rose from 17.7% at baseline to 35.4% at the last visit. At the latest time point available for analysis, 76% of naive and 74% of those who had switched had HIV-1 RNA loads of <50 copies/ml, while 59% of salvage patients achieved this level of viral suppression. Factors associated with viral suppression at the latest visit were adequate adherence (OR: 2.58, 95% CI: 0.85-7.78, p < 0.001), first-line treatment (OR: 3.02, 95% CI: 1.52-6.00, p = 0.002), and baseline CD4 cells >400 cells/μl (OR: 2.34, 95% CI: 1.22-4.47, p = 0.010). Exposure to nevirapine for up to 4 years is safe. Liver toxicity is infrequent and generally mild. HDL cholesterol levels consistently increase over time and viral suppression is maintained.

UR - http://www.scopus.com/inward/record.url?scp=33646123516&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33646123516&partnerID=8YFLogxK

U2 - 10.1089/aid.2006.22.321

DO - 10.1089/aid.2006.22.321

M3 - Article

C2 - 16623634

AN - SCOPUS:33646123516

VL - 22

SP - 321

EP - 329

JO - AIDS Research and Human Retroviruses

JF - AIDS Research and Human Retroviruses

SN - 0889-2229

IS - 4

ER -